Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2009 7
2010 7
2011 6
2012 4
2013 3
2014 2
2015 6
2016 10
2017 17
2018 25
2019 28
2020 41
2021 65
2022 37
2023 26
2024 17

Text availability

Article attribute

Article type

Publication date

Search Results

260 results

Results by year

Filters applied: . Clear all
Page 1
COVID-19 and ischemic stroke.
Sagris D, Papanikolaou A, Kvernland A, Korompoki E, Frontera JA, Troxel AB, Gavriatopoulou M, Milionis H, Lip GYH, Michel P, Yaghi S, Ntaios G. Sagris D, et al. Among authors: gavriatopoulou m. Eur J Neurol. 2021 Nov;28(11):3826-3836. doi: 10.1111/ene.15008. Epub 2021 Jul 17. Eur J Neurol. 2021. PMID: 34224187 Free PMC article. Review.
Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study.
Usmani SZ, Quach H, Mateos MV, Landgren O, Leleu X, Siegel D, Weisel K, Gavriatopoulou M, Oriol A, Rabin N, Nooka A, Qi M, Beksac M, Jakubowiak A, Ding B, Zahlten-Kumeli A, Yusuf A, Dimopoulos M. Usmani SZ, et al. Among authors: gavriatopoulou m. Lancet Oncol. 2022 Jan;23(1):65-76. doi: 10.1016/S1470-2045(21)00579-9. Epub 2021 Dec 3. Lancet Oncol. 2022. PMID: 34871550 Clinical Trial.
Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial.
Grosicki S, Simonova M, Spicka I, Pour L, Kriachok I, Gavriatopoulou M, Pylypenko H, Auner HW, Leleu X, Doronin V, Usenko G, Bahlis NJ, Hajek R, Benjamin R, Dolai TK, Sinha DK, Venner CP, Garg M, Gironella M, Jurczyszyn A, Robak P, Galli M, Wallington-Beddoe C, Radinoff A, Salogub G, Stevens DA, Basu S, Liberati AM, Quach H, Goranova-Marinova VS, Bila J, Katodritou E, Oliynyk H, Korenkova S, Kumar J, Jagannath S, Moreau P, Levy M, White D, Gatt ME, Facon T, Mateos MV, Cavo M, Reece D, Anderson LD Jr, Saint-Martin JR, Jeha J, Joshi AA, Chai Y, Li L, Peddagali V, Arazy M, Shah J, Shacham S, Kauffman MG, Dimopoulos MA, Richardson PG, Delimpasi S. Grosicki S, et al. Among authors: gavriatopoulou m. Lancet. 2020 Nov 14;396(10262):1563-1573. doi: 10.1016/S0140-6736(20)32292-3. Lancet. 2020. PMID: 33189178 Clinical Trial.
Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma.
Chari A, Vogl DT, Gavriatopoulou M, Nooka AK, Yee AJ, Huff CA, Moreau P, Dingli D, Cole C, Lonial S, Dimopoulos M, Stewart AK, Richter J, Vij R, Tuchman S, Raab MS, Weisel KC, Delforge M, Cornell RF, Kaminetzky D, Hoffman JE, Costa LJ, Parker TL, Levy M, Schreder M, Meuleman N, Frenzel L, Mohty M, Choquet S, Schiller G, Comenzo RL, Engelhardt M, Illmer T, Vlummens P, Doyen C, Facon T, Karlin L, Perrot A, Podar K, Kauffman MG, Shacham S, Li L, Tang S, Picklesimer C, Saint-Martin JR, Crochiere M, Chang H, Parekh S, Landesman Y, Shah J, Richardson PG, Jagannath S. Chari A, et al. Among authors: gavriatopoulou m. N Engl J Med. 2019 Aug 22;381(8):727-738. doi: 10.1056/NEJMoa1903455. N Engl J Med. 2019. PMID: 31433920 Clinical Trial.
A revised international prognostic score system for Waldenström's macroglobulinemia.
Kastritis E, Morel P, Duhamel A, Gavriatopoulou M, Kyrtsonis MC, Durot E, Symeonidis A, Laribi K, Hatjiharissi E, Ysebaert L, Vassou A, Giannakoulas N, Merlini G, Repousis P, Varettoni M, Michalis E, Hivert B, Michail M, Katodritou E, Terpos E, Leblond V, Dimopoulos MA. Kastritis E, et al. Among authors: gavriatopoulou m. Leukemia. 2019 Nov;33(11):2654-2661. doi: 10.1038/s41375-019-0431-y. Epub 2019 May 22. Leukemia. 2019. PMID: 31118465
Metabolic Disorders in Multiple Myeloma.
Gavriatopoulou M, Paschou SA, Ntanasis-Stathopoulos I, Dimopoulos MA. Gavriatopoulou M, et al. Int J Mol Sci. 2021 Oct 22;22(21):11430. doi: 10.3390/ijms222111430. Int J Mol Sci. 2021. PMID: 34768861 Free PMC article. Review.
Ibrutinib for rituximab-refractory Waldenström macro-globulinemia.
Gavriatopoulou M, Kastritis E, Dimopoulos MA. Gavriatopoulou M, et al. Oncotarget. 2017 Dec 18;9(16):12536-12537. doi: 10.18632/oncotarget.23400. eCollection 2018 Feb 27. Oncotarget. 2017. PMID: 29560081 Free PMC article. No abstract available.
Cholangiocarcinoma: investigations into pathway-targeted therapies.
Ntanasis-Stathopoulos I, Tsilimigras DI, Gavriatopoulou M, Schizas D, Pawlik TM. Ntanasis-Stathopoulos I, et al. Among authors: gavriatopoulou m. Expert Rev Anticancer Ther. 2020 Sep;20(9):765-773. doi: 10.1080/14737140.2020.1807333. Epub 2020 Aug 16. Expert Rev Anticancer Ther. 2020. PMID: 32757962 Review.
IMiDs for myeloma induced renal impairment.
Gavriatopoulou M, Terpos E, Dimopoulos MA. Gavriatopoulou M, et al. Oncotarget. 2018 Oct 26;9(84):35476-35477. doi: 10.18632/oncotarget.26270. eCollection 2018 Oct 26. Oncotarget. 2018. PMID: 30464802 Free PMC article. No abstract available.
260 results